Diabetes drug shows promise for weight loss in new study
NCT ID NCT06427083
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study tracks 200 adults with type 2 diabetes to see if enavogliflozin helps them lose weight over 24 weeks. Participants take the drug as part of their normal care. The main goals are changes in body weight and BMI. This is an observational study, not a cure, but aims to improve disease management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kyung Hee University Medical Center
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.